MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Viatris Inc

Closed

SectorHealthcare

9.96 -1.78

Overview

Share price change

24h

Current

Min

9.91

Max

10.16

Key metrics

By Trading Economics

Income

3B

-4.6M

Sales

328M

3.6B

Dividend yield

4.71

Profit margin

-0.128

Employees

32,000

EBITDA

2.9B

578M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+1.08% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

4.71%

2.94%

Next Earnings

6 lis 2025

Next Dividend date

12 gru 2025

Next Ex Dividend date

21 lis 2025

Market Stats

By TradingEconomics

Market Cap

1.3B

12B

Previous open

11.74

Previous close

9.96

News Sentiment

By Acuity

50%

50%

183 / 371 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Viatris Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

7 paź 2025, 16:58 UTC

Earnings

BMW Trims 2025 View, Citing Weaker Performance in China

7 paź 2025, 23:43 UTC

Market Talk

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7 paź 2025, 23:36 UTC

Market Talk

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7 paź 2025, 23:19 UTC

Market Talk

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7 paź 2025, 22:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 paź 2025, 22:50 UTC

Market Talk

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7 paź 2025, 22:40 UTC

Market Talk

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7 paź 2025, 21:56 UTC

Market Talk

Global Equities Roundup: Market Talk

7 paź 2025, 21:56 UTC

Market Talk

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7 paź 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

7 paź 2025, 20:44 UTC

Hot Stocks

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7 paź 2025, 19:42 UTC

Market Talk

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7 paź 2025, 19:23 UTC

Acquisitions, Mergers, Takeovers

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7 paź 2025, 19:07 UTC

Market Talk

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7 paź 2025, 19:02 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7 paź 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

7 paź 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

7 paź 2025, 16:20 UTC

Market Talk

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7 paź 2025, 16:15 UTC

Market Talk

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7 paź 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7 paź 2025, 15:37 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 paź 2025, 15:37 UTC

Market Talk

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7 paź 2025, 15:33 UTC

Market Talk

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7 paź 2025, 15:25 UTC

Market Talk

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7 paź 2025, 15:15 UTC

Market Talk

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7 paź 2025, 15:04 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

7 paź 2025, 15:04 UTC

Market Talk

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7 paź 2025, 14:56 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 paź 2025, 14:56 UTC

Market Talk

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7 paź 2025, 14:52 UTC

Earnings

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Peer Comparison

Price change

Viatris Inc Forecast

Price Target

By TipRanks

1.08% upside

12 Months Forecast

Average 10.25 USD  1.08%

High 14 USD

Low 8 USD

Based on 4 Wall Street analysts offering 12 month price targets forViatris Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

4 ratings

0

Buy

3

Hold

1

Sell

Technical Score

By Trading Central

8.48 / N/ASupport & Resistance

Short Term

Bullish Evidence

Intermediate Term

Very Strong Bullish Evidence

Long Term

Strong Bearish Evidence

Sentiment

By Acuity

183 / 371 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Viatris Inc

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
help-icon Live chat